Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Nurix Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Nurix Therapeutics's R&D Expenses for the twelve months ending Aug 31, 2026 was $334.07M, up 11.0% year over year. For fiscal 2025 it was $316.90M, up 43.0% from the year before. The highest annual figure on record is $316.90M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $316.90M | +43.0% |
| FY2024 | Nov 30, 2024 | $221.63M | +17.2% |
| FY2023 | Nov 30, 2023 | $189.15M | +2.5% |
| FY2022 | Nov 30, 2022 | $184.50M | +58.5% |
| FY2021 | Nov 30, 2021 | $116.43M | +75.1% |
| FY2020 | Nov 30, 2020 | $66.49M | +47.7% |
| FY2019 | Nov 30, 2019 | $45.03M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $79.26M | -8.0% |
| Q2 FY2026CQ2 2026 | May 31, 2026 | $87.65M | +12.2% |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | $84.14M | +20.8% |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | $83.02M | +23.5% |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | $86.12M | +55.2% |
| Q2 FY2025CQ2 2025 | May 31, 2025 | $78.10M | +59.6% |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | $69.66M | +39.3% |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | $67.22M | +35.2% |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | $55.48M | +15.9% |
| Q2 FY2024CQ2 2024 | May 31, 2024 | $48.92M | +6.9% |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | $50.01M | +9.1% |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | $49.71M | +7.8% |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | $47.86M | +0.2% |
| Q2 FY2023CQ2 2023 | May 31, 2023 | $45.76M | -3.6% |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | $45.82M | +6.2% |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | $46.11M | +26.2% |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | $47.76M | +54.5% |
| Q2 FY2022CQ2 2022 | May 31, 2022 | $47.49M | +82.7% |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | $43.14M | +87.5% |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | $36.53M | +78.7% |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | $30.91M | +63.2% |
| Q2 FY2021CQ2 2021 | May 31, 2021 | $25.99M | +83.8% |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | $23.00M | +77.4% |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | $20.45M | +59.4% |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | $18.94M | +72.0% |
| Q2 FY2020CQ2 2020 | May 31, 2020 | $14.14M | – |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | $12.97M | – |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | $12.82M | – |
| Q3 FY2019CQ3 2019 | Aug 31, 2019 | $11.01M | – |
See a number that looks wrong?